Howard McLeod
Howard McLeod
Medical Director, Geriatric Oncology Consortium
Verified email at the-goc.org
Title
Cited by
Cited by
Year
Pharmacogenomics—drug disposition, drug targets, and side effects
WE Evans, HL McLeod
New England Journal of Medicine 348 (6), 538-549, 2003
21652003
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
MJ Rieder, AP Reiner, BF Gage, DA Nickerson, CS Eby, HL McLeod, ...
New England Journal of Medicine 352 (22), 2285-2293, 2005
16242005
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ...
Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008
8112008
Doxorubicin pathways: pharmacodynamics and adverse effects
CF Thorn, C Oshiro, S Marsh, T Hernandez-Boussard, H McLeod, ...
Pharmacogenetics and genomics 21 (7), 440, 2011
8062011
Genomics and drug response
L Wang, HL McLeod, RM Weinshilboum
New England Journal of Medicine 364 (12), 1144-1153, 2011
5982011
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity
MM Ameyaw, F Regateiro, T Li, X Liu, M Tariq, A Mobarek, N Thornton, ...
Pharmacogenetics and Genomics 11 (3), 217-221, 2001
5432001
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer
Y Wang, T Jatkoe, Y Zhang, MG Mutch, D Talantov, J Jiang, HL McLeod, ...
Journal of clinical oncology 22 (9), 1564-1571, 2004
5222004
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
HL McLeod, EY Krynetski, MV Relling, WE Evans
Leukemia 14 (4), 567-572, 2000
4892000
UGT1A1* 28 genotype and irinotecan-induced neutropenia: dose matters
JM Hoskins, RM Goldberg, P Qu, JG Ibrahim, HL McLeod
Journal of the National Cancer Institute 99 (17), 1290-1295, 2007
4872007
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs
S Zhou, SY Chan, BC Goh, E Chan, W Duan, M Huang, HL McLeod
Clinical pharmacokinetics 44 (3), 279-304, 2005
4822005
Platinum neurotoxicity pharmacogenetics
SR McWhinney, RM Goldberg, HL McLeod
Molecular cancer therapeutics 8 (1), 10-16, 2009
4762009
PI3K/Akt/mTOR pathway as a target for cancer therapy
D Morgensztern, HL McLeod
Anti-cancer drugs 16 (8), 797-803, 2005
4422005
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine
AJ Black, HL McLeod, HA Capell, RH Powrie, LK Matowe, SC Pritchard, ...
Annals of internal medicine 129 (9), 716-718, 1998
4391998
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
X Wei, HL McLeod, J McMurrough, FJ Gonzalez, P Fernandez-Salguero
The Journal of clinical investigation 98 (3), 610-615, 1996
4211996
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
BF Gage, C Eby, PE Milligan, GA Banet, JR Duncan, HL McLeod
Thrombosis and haemostasis 91 (01), 87-94, 2004
3902004
The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations.
ESR Collie-Duguid, SC Pritchard, RH Powrie, J Sludden, DA Collier, T Li, ...
Pharmacogenetics 9 (1), 37-42, 1999
3851999
PHARMACOGENOMICS: Unlocking the Human Genome for Better Drug Therapy
HL McLeod, WE Evans
Annual review of pharmacology and toxicology 41 (1), 101-121, 2001
3762001
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
GJ Peters, HHJ Backus, S Freemantle, B Van Triest, G Codacci-Pisanelli, ...
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587 (2-3 …, 2002
3672002
Strategies for enzyme/prodrug cancer therapy
G Xu, HL McLeod
Clinical Cancer Research 7 (11), 3314-3324, 2001
3362001
Carbamazepine, HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations
PB Ferrell, HL McLeod
Future Medicine Ltd 9 (10), 1543-1546, 2008
3262008
The system can't perform the operation now. Try again later.
Articles 1–20